Clinical Trials
12 trialsNCT07612215 2026-05-28
Elacestrant in Advanced Triple Positive Breast Cancer
NYU Langone Health
Phase 1/2 Recruiting
NCT07395336 2026-05-14
COMBINE-01
European Institute of Oncology
Phase 2 Recruiting
NCT07242352 2026-05-06
ADAPTela
West German Study Group
Phase 3 Recruiting
NCT05982093 2026-04-24
SOLTI-2104
SOLTI Breast Cancer Research Group
Phase 2 Recruiting
NCT07198724 2026-04-09
ERADICATE
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT07222215 2026-01-22
CAPELA
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05826964 2026-01-13
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
Phase 2 Active not recruiting
NCT06691035 2025-12-04
Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
NCT06201234 2025-12-01
ELEMENT
GBG Forschungs GmbH
Phase 2 Recruiting
NCT07159451 2025-12-01
POP-ELA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Recruiting
NCT06062498 2025-10-20
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
Northwestern University
Phase 2 Recruiting
NCT04797728 2022-10-26
ELIPSE
SOLTI Breast Cancer Research Group
Phase EARLY_PHASE1 Completed